Compare IDEXX Laboratories, Inc. (IDXX) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Prospect Capital Corporation — how do they compare? IDEXX Laboratories, Inc. trades at $573.33 (market cap $46.22B), while Prospect Capital Corporation trades at $2.29 (market cap $1.14B). The key difference: IDEXX Laboratories, Inc. is far larger — about 40.5× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 21.93% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | PSEC | |
|---|---|---|
Market Cap | $46.22B | $1.14B |
Sector | Health | Financials |
52-Week High | $766.68 | $3.05 |
52-Week Low | $526.44 | $2.11 |
Enterprise Value | $47.12B | — |
Dividend Yield | — | 21.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Prospect Capital Corporation (PSEC) trades at $2.285, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows mixed fundamentals with a low P/B ratio of 0.39 but negative revenue and net income margins. Recent earnings have consistently beaten expectations, and the company maintains regular dividend payments of $0.04 per share. Analyst sentiment is divided with 25% buy ratings, 55% hold, and 20% sell recommendations.
PSEC presents a high-risk, high-yield opportunity trading at a significant discount to book value. The investment case hinges on the company's ability to stabilize revenue and return to profitability while maintaining its dividend distribution. Key risks include persistent negative revenue trends, high leverage costs, and market skepticism about portfolio quality despite recent successful exits like the Valley Electric sale generating 4.8x returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
